Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis.

ABSTRACT: Osteosarcoma (OS), a highly malignant primary bone tumor, is characterized by early metastasis, drug resistance, and a resultant poor prognosis, leading to significant disability and mortality. While diverse treatment modalities exist, their therapeutic efficacy remains limited, underscoring the urgent need to investigate effective targeted therapies. Sulfasalazine (SAS), a commonly used anti-inflammatory drug prescribed for nonspecific gastrointestinal diseases, autoimmune rheumatic diseases, ankylosing spondylitis, and various skin conditions, has recently garnered attention for its potential as an anti-tumor agent, specifically its ability to induce ferroptosis, a novel form of regulated cell death. This presents a promising new avenue for OS treatment. Ferroptosis plays a critical role

SUBMITTER: Qin Q 

PROVIDER: S-EPMC12361513 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature